Expression profile of Imatinib treated BAF3 -BCR-ABL cells. Mus musculus

BAF3 cells harboring constitutively expressing BCR-ABL were grown with or without IL-3 supplement and treated with Imatinib and live cells from the IL-3 and without IL-3 were sorted by FACS. Overall design: Cell growing without growth factor are sensitive to iamtinib and undergo apototis while cells grown with IL-3 are resistant. The expression profile of cells that will undergo death compared to that will survive was compared.